Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa.

44 A significant reduction in Sartorius score was seen after 6 weeks and an almost significant reduction after 12 weeks of active treatment when compared with placebo ( P =0.024 and P =0.07, respectively). 44 Adalimumab was well tolerated, in general, but the active group experienced an almost significantly greater number of adverse events (mostly mild infections). 44 Kimbal et al conducted

also in 1,858 other papers

At week 8, 25% of patients had at least 50% reduction of HSSI from baseline, but this did not reach statistical significance versus placebo (primary efficacy outcome was not achieved). 51 However, 20%–60% of patients, at week 8, reached a 25%–50% improvement in HSSI which was statistically significant compared with placebo. 51 DLQI also showed considerable improvement. 51 Recurrences occurred after discontinuation of treatment.

also in 111,027 other papers